1-androsterone.

Prohormone products routinely bundle milk thistle because androgen precursors undergo extensive hepatic first-pass metabolism and some carry documented liver strain. Silymarin has established antioxidant activity in liver tissue. Including it does not remove the underlying hepatic burden and should not be read as making the primary compound suitable for use. The pairing is formulation convention rather than a demonstrated protective combination.

N-acetylcysteine supplies cysteine, the rate-limiting amino acid for glutathione synthesis, and glutathione is central to hepatic phase two conjugation. Compounds cleared through the liver draw on that capacity. This is settled biochemistry about liver conjugation, not evidence that adding NAC makes an androgen precursor advisable. The pairing appears in stack design for that reason.

Oral androgen precursors suppress HDL cholesterol, an effect well described across the androgen class. Omega-3 fatty acids act mainly on triglycerides, which is a different lipid fraction. So the pairing does not cancel the specific change the precursor causes. That mismatch is worth stating plainly because the combination is often sold as offsetting.

Zinc participates in testicular steroid synthesis and in the regulation of aromatase, the enzyme that converts androgens to oestrogens. Low zinc status is associated with reduced endogenous androgen production. That biochemistry is settled, and it is separate from the question of whether exogenous androgen precursors are a reasonable thing to take. Zinc does not offset suppression of the hypothalamic-pituitary-gonadal axis.

Androgens and their metabolites are cleared largely as glucuronide conjugates. Calcium D-glucarate inhibits intestinal beta-glucuronidase, which reduces deconjugation and reabsorption of those conjugates. The direction of effect is toward faster net clearance. The magnitude in people taking androgen precursors has not been measured.

DIM shifts oestrogen hydroxylation toward the 2-hydroxy pathway and away from 16-alpha-hydroxylation. It is included in androgen precursor stacks on the assumption of managing aromatised metabolites. DIM does not inhibit aromatase itself, so it changes what happens to oestrogens rather than how much is formed. That distinction is usually lost in product marketing.

Tongkat ali is combined with androgen precursors in products positioned around male hormone support. Its own human evidence base is small and mostly short-duration. Stacking a botanical acting on endogenous production with a compound that suppresses endogenous production works against itself directionally. That contradiction is worth flagging rather than presenting the pair as complementary.

Short human studies have reported that boron intake shifts the ratio of free to bound testosterone by lowering sex hormone binding globulin. The trials are small and the endpoint is a hormone measurement rather than a functional outcome. Boron is a common inclusion in androgen-positioned stacks for this reason. The evidence sits well below anything that would justify a firm claim.